Comparator: amlodipine besylate — Competitive Intelligence Brief

Comparator: amlodipine besylate (Comparator: amlodipine besylate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker (dihydropyridine). Area: Cardiovascular.

phase 3 Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel Cardiovascular Small molecule

Target snapshot

Comparator: amlodipine besylate (Comparator: amlodipine besylate) — Organon and Co. Amlodipine besylate is a calcium channel blocker that relaxes blood vessels and reduces blood pressure by inhibiting calcium influx into vascular smooth muscle cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: amlodipine besylate TARGET	Comparator: amlodipine besylate	Organon and Co	phase 3	Calcium channel blocker (dihydropyridine)	L-type voltage-gated calcium channel
Amlodipine + Perindopril	Amlodipine + Perindopril	Centre for Chronic Disease Control, India	marketed	Calcium channel blocker + ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Losartan (+) amlodipine	Losartan (+) amlodipine	Organon and Co	marketed	Angiotensin II receptor blocker + calcium channel blocker combination	AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)
Calcium Channel Blockers	Calcium Channel Blockers	Hospital de Clinicas de Porto Alegre	marketed	Calcium channel blocker	L-type voltage-gated calcium channel
Lercanidipine/enalapril fixed combination	Lercanidipine/enalapril fixed combination	Meir Medical Center	marketed	Calcium channel blocker / ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
Losartan/amlodipine or losartan/hydrochlorothiazide	Losartan/amlodipine or losartan/hydrochlorothiazide	Yokohama City University Medical Center	marketed	Angiotensin II receptor blocker combination (ARB + calcium channel blocker or ARB + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels (amlodipine) or sodium-chloride cotransporter (hydrochlorothiazide)
trandolapril/verapamil	trandolapril/verapamil	Abbott	marketed	ACE inhibitor / calcium channel blocker combination	Angiotensin-converting enzyme (ACE); L-type voltage-gated calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker (dihydropyridine) class)

1. Bayer · 2 drugs in this class
2. Beijing Tiantan Hospital · 2 drugs in this class
3. GlaxoSmithKline · 1 drug in this class
4. Guangzhou First People's Hospital · 1 drug in this class
5. Organon and Co · 1 drug in this class
6. Peking University First Hospital · 1 drug in this class
7. Pfizer Inc. · 1 drug in this class
8. SK Chemicals Co., Ltd. · 1 drug in this class
9. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
10. Shanghai Shyndec Pharmaceutical Co., Ltd. · 1 drug in this class